PeptiDream subsidiary PDR Pharma formally announced plans to build a new plant in Chiba Prefecture's Kazusa Akademia Park and signed a site agreement. The investment is expected to total approximately ¥16.5 billion, with construction scheduled to begin in 2027 and completion targeted for September 2028.
The new plant will be built on the Production 2B site in Chiba Prefecture's Kazusa Akademia Park, with a total floor area of 5,364.46 square metres and a site area of approximately 5.7 hectares. Total investment is expected to be approximately ¥16.5 billion, comprising ¥11 billion for the building and ¥5.5 billion for equipment and other items. The plant is expected to employ 25 people.
In addition to manufacturing PET products, the business will conduct process development, manufacturing and shipment of radioisotope therapeutics and diagnostic agents. The product range will use radioisotopes including Cu-64, Lu-177 and Ac-225.
Construction is scheduled to begin in 2027, with completion targeted for September 2028. The company is considering using long-term bank borrowings, government support measures, tax incentives and subsidies to secure funding. On the same day, a site agreement was signed between Chiba Prefecture and the council.
Future prospects include strengthening domestic supply and eventually exporting to the Asia-Pacific region.